{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["PF-08634404"]],"indication":"locally advanced or metastatic non-small cell lung cancer","name":"Symbiotic-Lung-01","nct_id":"NCT07222566","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=symbiotic-lung-01-nct07222566. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive PF-08634404 combined with chemotherapy regimen 1, followed by maintenance therapy with PF-08634404.","label":"Arm A","type":"EXPERIMENTAL"},{"description":"Participants will receive pembrolizumab combined with chemotherapy regimen 1, followed by maintenance therapy with pembrolizumab.","label":"Arm B","type":"ACTIVE_COMPARATOR"},{"description":"Participants will receive PF-08634404 combined with chemotherapy regimen 2, followed by maintenance therapy with PF-08634404 and chemotherapy.","label":"Arm C","type":"EXPERIMENTAL"},{"description":"Participants will receive pembrolizumab combined with chemotherapy regimen 2, followed by maintenance therapy with pembrolizumab and chemotherapy.","label":"Arm D","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-08-26","type":"ESTIMATED"},"conditions":["Advanced Non-Small Cell Lung Cancer","Non-Small Cell Lung Cancer","Carcinoma, Non-Small-Cell Lung","Carcinoma, Non-Small-Cell Lung (NSCLC)","Metastatic Non Small Cell Lung Cancer","Lung Cancer"],"enrollment":{"count":1410,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"PF-08634404","otherNames":[],"type":"BIOLOGICAL"},{"name":"Pembrolizumab","otherNames":[],"type":"BIOLOGICAL"},{"name":"Chemotherapy Regimen 1","otherNames":[],"type":"DRUG"},{"name":"Chemotherapy Regimen 2","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-08","lead_sponsor":"Pfizer","official_title":"AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-02-27","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival","timeFrame":"Approximately 39 months"},{"measure":"Progression Free Survival (PFS) assessed by blinded independent central review (BICR)","timeFrame":"Approximately 32 months"}],"references":[],"start_date":{"date":"2026-01-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT07222566"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/symbiotic-lung-01-nct07222566"}